More general, the therapeutic induction of an immunogenic form of tumor cell death will not be achieved by a combination of H-1PV with gemcitabine-like drugs which employ cGAS/STING/TBK1-mediated signaling to trigger IFN production. The gene discussed is CGAS; the disease is neoplasm.